Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chitosan-encapsulated gloriosa superba tuber nanoparticles
- Development stage
- Preclinical
- Lead developer
- Bharathiar University
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Chitosan-encapsulated Gloriosa superba tuber nanoparticles (CEGSTNs) are an experimental nano-formulation consisting of an extract from the tuber of the medicinal plant *Gloriosa superba* encapsulated within a chitosan polymer matrix. Developed primarily for the treatment of cervical cancer, CEGSTNs exert their anticancer effects by downregulating the expression of the Spindle and kinetochore-associated complex subunit 3 (SKA3). This downregulation leads to the inactivation of the PI3K/AKT/mTOR signaling pathway, which subsequently inhibits cell proliferation and induces apoptosis in cancer cells. Preclinical studies in HeLa cell lines and Wistar rat models have demonstrated significant efficacy and a favorable safety profile, with no observed acute toxicity or adverse effects on hematological or biochemical parameters.
- Other names
- Chitosan Encapsulated G. superba Tuber Nanoparticles
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)SKA3 (Spindle and kinetochore-associated complex subunit 3)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on chitosan-encapsulated gloriosa superba tuber nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chitosan-encapsulated gloriosa superba tuber nanoparticles.